Vyvanse Cost in District of Columbia 2026

What Vyvanse Actually Costs in DC Right Now

The sticker price and the price you pay are two very different numbers. Takeda's wholesale acquisition cost for Vyvanse sits at approximately $390 for a 30-day supply regardless of capsule strength (20 mg through 70 mg). Yet the average DC resident with a GoodRx-style coupon pays about $35 per month at major retail chains in 2026.

Why the Gap Is So Large

Generic lisdexamfetamine dimesylate entered the US market in August 2023 after Takeda's patent exclusivity expired. That single event drove coupon-negotiated prices down sharply. According to the FDA's Orange Book, multiple manufacturers now hold approved ANDAs for lisdexamfetamine, and retail competition across CVS, Rite Aid, Walgreens, and Giant Food locations in the District has kept cash prices low. The FDA Orange Book confirms lisdexamfetamine generic approvals.

Strength-by-Strength Price Snapshot

Coupon pricing in DC does not vary dramatically by capsule strength. Whether a patient fills 30 mg or 60 mg, the cash price with a GoodRx or RxSaver coupon lands between $30 and $45 at most DC-area pharmacies. The 70 mg capsules occasionally run slightly higher at independent pharmacies that have less negotiating power with pharmacy benefit managers.

Patients should present the coupon before the pharmacist runs insurance. Running insurance first locks the claim into the adjudication system; coupon pricing requires a separate cash transaction and cannot be combined with federal insurance benefits (Medicare Part D or Medicaid) under federal anti-kickback rules. CMS guidance on copay coupons and federal programs is available from CMS.

The Schedule II Constraint

Because lisdexamfetamine is DEA Schedule II, DC pharmacies cannot dispense more than a 30-day supply at one time, and prescriptions cannot be refilled. The DEA's Controlled Substances Act scheduling page explains Schedule II supply limits. Patients need a new written or electronic prescription each month, which may factor into telehealth visit frequency and associated copay costs.

DC Medicaid Coverage for Vyvanse

DC Medicaid (administered through DC Department of Health Care Finance under the AmeriHealth Caritas DC and MedStar Family Choice managed care plans) covers lisdexamfetamine for both ADHD and binge-eating disorder (BED) with a prior authorization. DC DHCF managed care plan information is available at dhcf.dc.gov.

Prior Authorization Requirements

PA criteria across DC Medicaid plans typically require:

• A documented ADHD or BED diagnosis meeting DSM-5 criteria
• Failure of or clinical contraindication to at least one formulary stimulant (commonly amphetamine salts or methylphenidate)
• Prescriber attestation that the patient is 6 years of age or older (ADHD) or 18 years or older (BED)
• A face-to-face or synchronous telehealth evaluation within the prior 12 months

The American Academy of Child and Adolescent Psychiatry notes that stimulant medications have the largest evidence base for ADHD treatment, and that access barriers like PA requirements meaningfully delay care for Medicaid-enrolled children. AACAP's practice parameters are indexed on PubMed.

What Happens If PA Is Denied

Denials are common on first submission if documentation is incomplete. DC Medicaid enrollees have the right to a fair hearing within 90 days of denial. The prescriber can also request a peer-to-peer review with the plan's medical director, which reverses denials in many cases when trial-and-failure documentation is provided. Patients waiting for PA resolution may use a manufacturer bridge program or a cash-pay coupon in the interim, but cannot combine coupon pricing with Medicaid claims.

BED-Specific Coverage Path

Vyvanse received FDA approval for moderate-to-severe binge-eating disorder in adults in January 2015, making it the only Schedule II stimulant with that labeled indication. The FDA approval history is documented in the Vyvanse prescribing information. DC Medicaid coverage for BED follows the same PA pathway but requires a psychiatry or behavioral health note confirming the BED diagnosis and ruling out anorexia nervosa or bulimia nervosa as primary conditions.

Generic Lisdexamfetamine in DC: The Cheapest Brand-Name Alternative

Generic lisdexamfetamine is bioequivalent to Vyvanse under FDA standards. The FDA requires that generic formulations demonstrate an AUC and Cmax within 80 to 125 percent of the reference listed drug in pharmacokinetic studies. FDA bioequivalence standards are described in 21 CFR Part 320.

Clinical Evidence for Lisdexamfetamine

The core efficacy data underlying all lisdexamfetamine prescribing comes from a set of well-controlled trials. Wigal et al. (2017, N=315) demonstrated that lisdexamfetamine produced statistically significant reductions in ADHD-RS-IV scores compared with placebo across a range of doses in adults, with effect sizes consistent across the 30 mg to 70 mg range. Wigal et al. 2017 on PubMed. The drug's mechanism involves conversion of the inactive prodrug to d-amphetamine after oral ingestion, a process that occurs in red blood cells and produces a smooth onset curve that reduces abuse liability compared with immediate-release amphetamine. Prodrug pharmacology is described in the FDA label.

Generic Pricing at DC Pharmacies

At major DC-area pharmacies, generic lisdexamfetamine with a coupon costs between $25 and $40 per 30-day supply in 2026. Patients whose insurance covers generics at a lower tier than brand-name drugs will generally pay a lower copay for the generic even when Vyvanse itself is covered. Prescribers should write "may substitute" on the prescription unless there is a clinical reason to require the brand.

Compounded Lisdexamfetamine in DC: Legality and Pricing

Compounded lisdexamfetamine prepared by a state-licensed 503A pharmacy is legal in the District of Columbia. 503A pharmacies compound for individual patient prescriptions under state board of pharmacy oversight, and DC's Board of Pharmacy has not issued any prohibition specific to lisdexamfetamine compounding. FDA's overview of 503A compounding pharmacies is available at fda.gov.

How 503A Differs from 503B

503A pharmacies compound patient-specific prescriptions. 503B outsourcing facilities produce large batches without individual prescriptions, are FDA-registered, and operate under current Good Manufacturing Practice standards. FDA's comparison of 503A and 503B frameworks is published on fda.gov. Compounded lisdexamfetamine for a DC patient must come from a 503A pharmacy, not a 503B facility, because lisdexamfetamine is not on FDA's drug shortage list (the condition required for 503B compounding of a commercially available drug).

What Compounded Lisdexamfetamine Costs in DC

Telehealth platforms that include compounding pharmacy services often bundle the compound into a monthly membership fee, effectively bringing the per-prescription cost to $0 for the compound itself. DC patients should verify that the compounding pharmacy holds a current DC Board of Pharmacy nonresident or in-state license before accepting a shipment. The DEA requires that compounded Schedule II substances be prescribed under the same rules as brand-name Schedule II drugs, so no automatic refills apply. DEA rules for compounded controlled substances are at deadiversion.usdoj.gov.

The HealthRX clinical team uses a three-tier decision framework when advising DC patients on lisdexamfetamine access. Tier 1: establish insurance coverage or Medicaid PA and use a formulary generic. Tier 2: if insurance denies or the patient is uninsured, use a GoodRx-type coupon for generic lisdexamfetamine at a DC retail pharmacy. Tier 3: if cost remains prohibitive, evaluate 503A compounded lisdexamfetamine through a licensed telehealth provider holding DEA and DC prescribing authority.

Telehealth Prescribing of Vyvanse in DC

DC law permits synchronous telehealth prescribing of controlled substances under the Ryan Haight Online Pharmacy Consumer Protection Act framework, provided the prescriber holds a valid DC medical license and a DEA registration that includes Schedule II authority. DEA telehealth prescribing rules are summarized at deadiversion.usdoj.gov.

Post-COVID Telehealth Flexibilities

During the COVID-19 public health emergency, the DEA temporarily waived the requirement for an in-person examination before prescribing Schedule II stimulants via telehealth. Those flexibilities were extended through December 31, 2025, and the DEA finalized new Special Registration rules in late 2024 to create a permanent pathway. DC patients who established care with a telehealth prescriber during the pandemic period can generally continue receiving prescriptions under the new Special Registration framework. DEA's Special Registration for telemedicine is described in the Federal Register.

What a DC Telehealth Visit Involves

A standard initial telehealth evaluation for ADHD or BED in DC includes a structured clinical interview, review of symptom rating scales (commonly the Adult ADHD Self-Report Scale or the Binge Eating Scale), medical history, blood pressure measurement (patient self-reported or from a recent in-person visit), and documentation of prior medication trials. The American Psychiatric Association's practice guideline for ADHD notes that stimulant prescribing decisions should include cardiovascular risk screening. APA practice guidelines are indexed on PubMed.

Follow-up visits for Schedule II renewals typically occur every 30 days and can remain fully telehealth in DC under current rules. Costs for telehealth visits range from $0 (Medicaid-covered platforms) to $150 to $299 per visit for cash-pay services.

Vyvanse Insurance Coverage in DC

Most commercial insurance plans sold on the DC Health Link marketplace include lisdexamfetamine on their formulary at Tier 3 or Tier 4. Tier placement determines the copay: Tier 3 copays in DC marketplace plans average $40 to $70 per 30-day fill, while Tier 4 specialty-drug copays may reach $100 to $150 before deductible requirements kick in.

Employer-Sponsored Plans

Large employer plans (subject to ERISA) set their own formularies and may differ significantly from marketplace plan formularies. DC federal government employees under the Federal Employees Health Benefits program have multiple plan options, several of which cover brand Vyvanse at Tier 3 after PA. Employees should check the specific plan's formulary drug list, not just the general FEHB brochure.

Medicare Part D

Medicare Part D plans cover lisdexamfetamine generics on most formularies. Brand Vyvanse may not be covered or may require step therapy through the generic first. Patients in the initial coverage phase pay their plan-specific copay; those who reach the catastrophic coverage threshold pay 5 percent or a small copay for the remainder of the benefit year. Medicare Part D formulary rules are explained by CMS.

Takeda Savings Card and Other DC Discount Programs

Takeda offers a co-pay savings card for commercially insured Vyvanse patients that can reduce out-of-pocket costs to $0 per fill, subject to a monthly and annual maximum benefit. The card is not valid for patients covered by federal insurance programs including Medicare, Medicaid, TRICARE, or any other government-funded plan.

How the Savings Card Works

Patients download or print the card from Takeda's website, present it at the pharmacy alongside their insurance card, and the pharmacy bills the insurance first. The savings card then covers the remaining patient liability up to the card's benefit cap. If insurance denies the claim entirely, the card does not function as a standalone cash-pay instrument. DC residents using the card at CVS or Walgreens generally see a $0 copay on commercially insured fills as long as the annual cap has not been reached.

Prescription Assistance Programs

Takeda's patient assistance program provides Vyvanse at no cost for uninsured or underinsured patients who meet income eligibility criteria (typically at or below 400 percent of the federal poverty level). Applications require proof of income, a completed prescriber enrollment form, and proof of DC residency. Processing time is typically two to four weeks. NeedyMeds maintains a database of manufacturer assistance programs.

GoodRx, RxSaver, Blink Health, and Cost Plus Drugs all offer coupon pricing for generic lisdexamfetamine at DC-area pharmacies. Cost Plus Drugs (Mark Cuban's pharmacy) listed lisdexamfetamine 70 mg at approximately $27 per 30-day supply for direct-to-patient shipping in early 2026, though availability for Schedule II substances through mail-order platforms depends on state-specific pharmacy licensing.

Safety Profile and Monitoring Expectations in DC Clinical Practice

Prescribers in DC are expected to follow the FDA-approved label's monitoring requirements regardless of whether care is delivered in person or via telehealth. The label requires baseline cardiovascular assessment, blood pressure and heart rate monitoring, height and weight tracking in pediatric patients, and screening for personal or family history of structural cardiac abnormalities. Full prescribing information including boxed warning is available at accessdata.fda.gov.

Boxed Warning

Vyvanse carries an FDA boxed warning for high abuse potential and dependence. The warning states that amphetamines have been extensively abused, and that prolonged administration may lead to drug dependence. DC prescribers must document the clinical rationale for stimulant selection in the medical record, particularly when treating BED, where the abuse liability context differs from childhood ADHD. The FDA's stimulant abuse potential guidance is at fda.gov.

Common Adverse Effects Affecting Adherence

The most frequently reported adverse effects leading to dose adjustment or discontinuation in clinical trials were decreased appetite (reported in 34.5 percent of adult ADHD patients on 70 mg versus 2.8 percent of placebo patients), insomnia (19.3 percent versus 7.9 percent), and dry mouth (26.3 percent versus 7.9 percent). These figures are drawn from the prescribing information tables at accessdata.fda.gov. Patients who experience significant appetite suppression may need a dose reduction to 30 mg or 40 mg rather than the standard titration target of 50 to 70 mg.

Drug Interactions Relevant to DC's Patient Population

DC has a high rate of antidepressant co-prescribing given its urban behavioral health environment. Monoamine oxidase inhibitors (MAOIs) are absolutely contraindicated with lisdexamfetamine; prescribers must ensure a 14-day washout before initiating. MAOI interaction data appear in the FDA label. Serotonergic agents co-prescribed with stimulants require monitoring for serotonin syndrome, particularly in patients on high-dose SSRIs or SNRIs. A 2022 systematic review of stimulant-serotonergic interactions is indexed on PubMed.

How DC Compares to Surrounding Jurisdictions

DC's cash-pay pricing for generic lisdexamfetamine runs roughly $5 to $10 lower per fill than neighboring Maryland and Virginia due to stronger pharmacy coupon competition among the District's high density of chain pharmacy locations. Medicaid coverage requirements are broadly similar across the three jurisdictions, though Maryland Medicaid's PA criteria allow nurse practitioners to submit PA requests without physician co-signature, a provision DC has not formally adopted. Maryland Medicaid formulary documentation is available through Maryland DHMH.

Virginia's Medicaid program (Medallion 4.0) covers lisdexamfetamine on a slightly shorter step-therapy sequence than DC, requiring only one prior stimulant trial rather than two. DC patients who cross the border for care should be aware that their DC Medicaid card will not cover prescriptions filled at Virginia or Maryland pharmacies unless their managed care plan has an out-of-network pharmacy agreement.